Gerstein Fisher’s PDL BioPharma, Inc. PDLI Stock Holding History

Gerstein Fisher’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-29,905	Closed	-$106K	–	443
2015 Q4	$106K	Sell	29,905 -1,197	-4%	-$5.01K	0.01%	397
2015 Q3	$156K	Sell	31,102 -4,083	-12%	-$23.4K	0.02%	390
2015 Q2	$226K	Buy	35,185 +1,403	+4%	+$9.4K	0.04%	367
2015 Q1	$238K	Buy	33,782 +196	+0.6%	+$1.42K	0.04%	356
2014 Q4	$258K	Sell	33,586 -4,612	-12%	-$36.5K	0.04%	320
2014 Q3	$285K	Buy	38,198 +1,279	+3%	+$11.9K	0.05%	302
2014 Q2	$357K	Buy	36,919 +66	+0.2%	+$588	0.07%	222
2014 Q1	$306K	Sell	36,853 -27,675	-43%	-$237K	0.06%	248
2013 Q4	$2.8M	Buy	64,528 +32,264	+100%	+$272K	0.1%	192
2013 Q3	$257K	Buy	32,264 +1,042	+3%	+$8.38K	0.06%	292
2013 Q2	$241K	Buy	+31,222	New	+$243K	0.06%	277

Other funds holding PDLI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gerstein Fisher's PDLI Position: Q1 2016 in Review

Gerstein Fisher sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 29,905 shares — an estimated $106K sold.

Gerstein Fisher first reported a position in PDLI in Q2 2013 and held it in 11 quarters. The position peaked at $2.8M in Q4 2013. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

Gerstein Fisher reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
Gerstein Fisher sold 29,905 PDL BioPharma, Inc. shares in Q1 2016, an estimated $106K.
Gerstein Fisher first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 11 quarters.
Gerstein Fisher's PDL BioPharma, Inc. position peaked at $2.8M in Q4 2013.
195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Gerstein Fisher's 13F filing for Q1 2016, filed 12 May 2016.